Brainomix Secures $21.2M Series B Funding to Transform Stroke Imaging Worldwide

Brainomix is proud to announce a groundbreaking funding achievement, having successfully raised $21,200,000 to further transform the way medical imaging is utilized in patient care. Since its inception as a spin-out from the University of Oxford in 2010, Brainomix has dedicated itself to turning ordinary scans into extraordinary insights because every patient deserves expert-level care, anywhere. This significant investment will accelerate the development and global expansion of Brainomix 360, our innovative AI-powered suite that enhances stroke imaging interpretation for neurologists, interventionalists, and radiologists. By integrating seamlessly with existing radiology workflows, Brainomix 360 delivers the right insights to the right people at the right time, ensuring that critical decisions in stroke and lung care are informed by state-of-the-art technology. The funds will be strategically deployed to enhance our research and development capabilities, expand our team of dedicated professionals, and scale our operations to meet the increasing demand in international markets. As we continue to push the boundaries of medical imaging with award-winning AI-powered imaging biomarkers and software solutions, this investment marks a major milestone in our journey to empower physicians worldwide with the tools needed for life-saving decisions. Our commitment to impacting patient outcomes remains at the heart of our mission, and with this new capital, we are set to unlock further potential in diagnostic accuracy and treatment efficiency. We invite healthcare professionals, partners, and stakeholders to reach out today to learn more about how Brainomix is revolutionizing the way imaging supports patient care and why our innovations are essential for enhancing stroke pathways globally.